Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00IAK
|
|||
| Former ID |
DNC008162
|
|||
| Drug Name |
1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one
|
|||
| Synonyms |
CHEMBL273139
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H19F3O3S
|
|||
| Canonical SMILES |
CCCCCCCCS(=O)(=O)CC(=O)C(F)(F)F
|
|||
| InChI |
1S/C11H19F3O3S/c1-2-3-4-5-6-7-8-18(16,17)9-10(15)11(12,13)14/h2-9H2,1H3
|
|||
| InChIKey |
LGBYSBJDEXOENJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| Liver carboxylesterase (CES1) | Target Info | Inhibitor | [1] | |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Drug metabolism - other enzymes | |||
| Metabolic pathways | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Anandamide degradation | |||
| Pathway Interaction Database | E2F transcription factor network | |||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Heroin metabolism | ||||
| Irinotecan Pathway | ||||
| Fluoropyrimidine Activity | ||||
| Phase I biotransformations, non P450 | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.